Travatan

(Travoprost)

ApprovedSmall molecule

Travoprost is used to treat high pressure inside the eye caused by glaucoma or other eye conditions. It works by helping fluid drain from the eye to lower the pressure.[2] Travatan is currently approved and in use across 5 indications[4].[1]

Travatan is one of 68 small molecule programs targeting Glaucoma. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GlaucomaActive, not recruiting

Ocular HypertensionActive, not recruiting

Neovascular GlaucomaActive, not recruiting

Exfoliation SyndromeApproved

Open-Angle GlaucomaActive, not recruiting

GlaucomaApproved

Active, not recruiting

Ocular HypertensionApproved

Active, not recruiting

Neovascular GlaucomaPreclinical

Active, not recruiting

Exfoliation SyndromeApproved

Approved

Open-Angle GlaucomaApproved

Active, not recruiting

Competition

Competitive Landscape

187 competitors in Ocular Hypertension

#DrugCompanyPhaseTrials

Travatan

Novartis

Approved

8 2

Alphagan

Novartis

Phase 3

1 3

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

9 4

Azopt

Novartis

Phase 3

1 5

Ocupress

AbbVie

Phase 3

1 6

LUMIGAN

AbbVie

Phase 3

2 7

Krytantek

AbbVie

Phase 3

2 8

Bimatoprost/timolol

AbbVie

Phase 3

4 9

Preservative-Free Tafluprost

Merck & Co.

Phase 3

2 10

Combigan

EEMS

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Study completion

NCT06066645

Clinical

Trials by Indication[1]

Ocular Hypertension8 trials

Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost

Completed·GGlaukos Corporation·Phase 4·NCT01443988·101 enrolled

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

Unknown status·GGlaukos Corporation·Phase 2·NCT06152861·250 enrolled

24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension

Completed·UUniversity of Parma·Phase 4·NCT01655758·61 enrolled

Show 5 more trials

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Completed·AAlcon Research·Phase 3·NCT00051142

Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed·AAlcon Research·Phase 2·NCT00670033·158 enrolled

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Completed·AAlcon Research·Phase 3·NCT00293761·109 enrolled

Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost

Completed·GGlaukos Corporation·Phase 4·NCT01444040·196 enrolled

Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension

Completed·AAlcon Research·Phase 4·NCT00061503

Glaucoma3 trials

Effects of Anti-Glaucoma Medications on the Ocular Surface

Terminated·MMassachusetts Eye and Ear Infirmary·Phase 4·NCT01315574·14 enrolled

Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents

Completed·GGlaukos Corporation·Phase 4·NCT02873806·53 enrolled

Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma

Completed·UUniversité de Montréal·N/A·NCT01711177·14 enrolled

Intraocular Pressure2 trials

Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure

Completed·PPrince of Songkla University·Phase 4·NCT02105311·60 enrolled

Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C

Terminated·AAlcon Research·Phase 2·NCT01312454·4 enrolled

MPA1 trial

Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

Completed·GGlaukos Corporation·Phase 2·NCT02754596·154 enrolled

Function1 trial

Stop Retinal Ganglion Cell Dysfunction Study

Terminated·UUniversity of Miami·Phase 3·NCT02390284·28 enrolled

4 more indications

Safety and Efficacy1 trial

Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT

Completed·OOcular Therapeutix, Inc.·Phase 3·NCT02914509·565 enrolled

Skin Pigmentation1 trial

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Completed·—·Phase 4·NCT00705757·89 enrolled

Neovascular Glaucoma1 trial

Effects of Travoprost on Neovascular Glaucoma

Withdrawn·FFederal University of São Paulo·N/A·NCT00441181·40 enrolled

Unspecified4 trials

Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone

Recruiting·GGlaukos Corporation·Phase 3·NCT06066645·230 enrolled

Performance of the Travoprost Intraocular Implant

Completed·GGlaukos Corporation·Phase 2·NCT06582732·210 enrolled

Travoprost Five Day Posology Study

Completed·AAlcon Research·Phase 2·NCT01114893·60 enrolled

Show 1 more trial

Study of Exchange of Travoprost Intraocular Implant

Completed·GGlaukos Corporation·Phase 2·NCT04615403·33 enrolled

Regulatory

FDA Approval Timeline[5]

Mar 16, 2001

TRAVATAN

NDA NDA021257

Sep 21, 2006

TRAVATAN Z

NDA NDA021994

May 15, 2014

IZBA

NDA NDA204822

Dec 13, 2023

IDOSE TR

NDA NDA218010

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for Travoprost. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Travatan drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Travoprost compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Travoprost. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA218010). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Travatan. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Prostanoid FP Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Novartis

Patent Landscape[6]

Patent Cliff

Sep 20, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8388941Sep 20, 2027

8323630Sep 20, 2027

9144561Mar 13, 2029

8754123May 19, 2029

8722735Oct 10, 2029

6 more patents

8178582Oct 10, 2029

8268299Oct 13, 2029

12201557Jun 18, 2030

10206813Oct 17, 2030

11426306Oct 17, 2030

12201555Feb 14, 2031

Travatan

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Ocular Hypertension8 trials

Glaucoma3 trials

Intraocular Pressure2 trials

MPA1 trial

Function1 trial

Safety and Efficacy1 trial

Skin Pigmentation1 trial

Neovascular Glaucoma1 trial

Unspecified4 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News